Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 14:16811693 Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening
According to the SmPC, tirzepatide frequently causes nausea, vomiting, diarrhoea, constipation, abdominal pain, and reduced appetite, particularly during the initial weeks of treatment or following dose escalation
doi: 10.3390/nu9040350, 195
If you have a history of drug allergies, talking with your healthcare provider can help ensure that semaglutide is the right choice for you